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Abstract
Background: Causal relationships have been previously established between smoking and various cancers. In
Cyprus, 39 % of men and 14 % of women reported daily smoking in 2008. The objective of this study was to
compare the incidence of tobacco-related cancers to all other cancers by district and rural–urban classification to
understand the impact of tobacco in Cyprus.
Methods: Data on lung, urinary bladder, oral, pharyngeal, head/neck, and laryngeal cancers were obtained from
the Cyprus Cancer Registry (1998–2008). There were 3,635 patients with tobacco-related cancers and 18,780 with
non-tobacco cancers. Univariate analysis comparing tobacco-related cancers and all other cancers were conducted
with regards to age at diagnosis, age groups, sex, smoking status, disease stage, and rural/urban status, with a
p-value of 0.05 considered significant. Smoking prevalence, lung cancer, and bladder cancer rates of Cyprus
were also compared to a number of other European countries.
Results: Patients with tobacco-related cancers were older than those with non-tobacco cancers (mean age
67.2 ± 12.4 vs. 62.4 ± 17.1, p < 0.0001). Among those with tobacco-related cancers, 80.1 % were male compared
to 45.4 % males with other cancer types. The proportion of ever smokers was higher among males compared to
females in urban and rural districts. Sub-districts 41 (Age Adjusted Rate (AAR) 41.9, 95 % CI: 35.7-48.1), 60 (AAR
40.3, 95 % CI: 35.2-45.3), and 50 (AAR 36.3, 95 % CI: 33.8-38.7) had the highest rates of tobacco-related cancers.
The overall tobacco-related cancer rate was the highest among males in urban districts (AAR 60.8, 95 % CI: 58.2-63.5).
Among tobacco-related cancers, lung cancer had the highest overall AAR (17.9 per 100,000) while head and neck
cancer had the lowest overall AAR (5.3 per 100,000). Additionally, even though Cypriot males aged 65–69 years old
exhibited higher smoking prevalence than other European countries, the overall lung and bladder cancer rates were
lower in Cyprus.
Conclusion: Despite the high proportion of smokers in Cyprus, cancer rates are low compared to other countries.
Future in-depth measurements of relevant risk factors and smoking exposure can help understand this phenomenon
and provide insights for cancer prevention.
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Introduction
Tobacco smoking represents the most preventable cause of
morbidity and mortality worldwide [1, 2]. It directly causes
approximately 5 million deaths globally every year, and in-
directly, through the effects of second-hand smoke, an add-
itional 600,000 deaths [3]. These trends are increasing and
it is projected that tobacco will be responsible for the death
of 8 million people annually by the year 2030 [1, 4, 5]. Fur-
thermore, mortality attributed to tobacco has been increas-
ing at a higher rate in developing countries, with higher
rates among men compared to women [2].
Tobacco smoke contains approximately 4,000 potentially
noxious chemicals, of which more than 69 have been clas-
sified as carcinogens [6, 7]. Smoking accounts for about
74 % of trachea, bronchus, and lung cancers, in addition to
a number of other cancers [1, 4, 5, 7]. Associations with to-
bacco smoking have also been found with liver, ureter,
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nasal cavity and sinus cancers [8]. Tobacco smoking is also
associated with an increased risk of other diseases includ-
ing raised rates of ischemic heart disease and stroke, dis-
eases of the respiratory system, and communicable
diseases [1, 6, 9, 10].
Tobacco smoking prevalence is increasing in many
parts of the world, including Cyprus, a small island in
the Eastern Mediterranean. The morbidity and mortality
attributable to tobacco can be estimated using several
models [1, 2, 11–13]. According to the 2004 World
Health Organization (WHO) estimates for adult
Cypriots aged 30 years and over, nearly 10 % of annual
deaths are attributable to tobacco [2]. Furthermore, one-
fifth of malignant neoplasm deaths are due to tobacco
consumption; this proportion increases to one-quarter
when only considering those who are 60–69 years of age
[2]. Tobacco is also responsible for nearly three-quarters
of deaths from trachea, bronchus and lung cancers [2].
To date there has not been systematic data collection on
the smoking prevalence in Cyprus [10, 14]. Surveys con-
ducted between 1989 and 2008 found that among male re-
spondents, smoking prevalence has been relatively stable
(between 38-43 %) [14–19]. However, prevalence doubled
among females, from 7 % in 1989 to 14 % in 2008 [14–19].
Adolescent smoking rates in Cyprus have also been investi-
gated and are comparable to other European and eastern
Mediterranean countries. In Cyprus middle schools (12–15
years old), 6-10 % of the students smoke regularly and 19-
28 % have tried smoking [14, 19]. Among high school
students, approximately one-quarter smoke regularly
and approximately half have tried smoking [14, 19].
The numbers increase even further when examining
only the 17–18 age groups [19]. Rates for other coun-
tries can range from 5 % in Greece (both boys and girls
11–15 year olds) to 8 % (boys) and 11 % (girls) in the
United Kingdom of the same age [10, 14, 19].
Although cancer incidence in Cyprus may be lower
than that of neighboring countries, it has slightly in-
creased between 1998 and 2008 [20], which suggests that
the high proportion of individuals who partake in
cigarette or other forms of smoking can eventually lead
to higher rates of cancer in the coming years due to the
lag period between tobacco exposure and disease onset.
The objective of this study was to compare the incidence
of several tobacco-related cancers to the incidence of all
other cancers by district and by rural–urban classifica-
tion and to other European countries to better under-
stand the impact of tobacco in Cyprus.
Methods
Ethical consent
The use of data in this study was approved by the
Cyprus National Bioethics Committee, reference number
ΕΕΒΚ ΕΠ 2012.01.26.
Data sources
The Cyprus Cancer Registry (CyCR) is a population-based
cancer registry established in 1998 with the support from
the Middle East Cancer Consortium (MECC) and the
National Cancer Institute, USA. The CyCR includes the
government-controlled southern part of the island of
Cyprus and is administered by the Cyprus Ministry of
Health (MOH). Patients who are permanent residents of
the area not under the effective control of the government
of the Republic of Cyprus (labelled as Turkish occupied
territory in Fig. 1) were not included in the analyses. Using
the classification system established by MECC, the CyCR
uses ICD-O-3 to record information on 57 different can-
cer types, and the CANREG4 software, used for registra-
tion, derives the appropriate ICD-10 codes [21, 22].
MECC conducted an audit in 1999 and found that the
CyCR accomplished 88 % case coverage. Since then, the
registry has improved, and based on a 2008 case finding
evaluation, the CyCR is estimated to accomplish 95 %
coverage of all cancer cases in government-controlled
Cyprus [22].
Data for this study were obtained from the CyCR and
contained a unique identifier (that was created and kept
by the Health Monitoring Unit (HMU)) and included
the year of diagnosis, sex, and age at diagnosis. In
addition, smoking data was obtained from the registry,
albeit it was not available for all patients. The missing
smoking information from the Cyprus registry included
in this study is comparable to the rates reported from
other cancer registries in the region [23]. Cancer data
were available for years 1998 – 2008. Annual age and
sex-specific population estimates by geographic region
were derived through linear regression analyses of the
population census data of 1992, 2001, and 2011 available
from the Cyprus statistical service. Due to a large popu-
lation increase between 2001 and 2011, growth estimates
rates were calculated independently between 1992 to
2001 and 2001 to 2011. Data on smoking prevalence by
urban/rural area of residence was obtained from the
Cyprus statistical service who collected this information
as part of their 2008 European Health Survey.
There are 5 districts in Cyprus: Ammochostos, Larnaka,
Lefkosia, Lemesos, and Pafos. Kyreneia as shown in Fig. 1
belongs to the Turkish occupied territory and therefore is
not considered a district of Cyprus. Each district is com-
prised of multiple municipalities, which are each assigned
a 4 digit code by the Cyprus statistical service. We col-
lapsed these municipalities according to the first 2 digits of
the code into 18 sub-districts, which served as the geo-
graphic areas for the cancer incidence analyses. All districts
contain urban and rural sub-districts, except Ammochos-
tos, which is considered primarily rural (Fig. 1).
Data used for the comparison with other European
countries was extracted from Cancer Incidence in Five
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Continents Plus (CI5 Plus) from the International
Agency for Research on Cancer [24]. Lung and bladder
cancer rates were from the years 1997–2007, which is
similar to the time period used in this study (1998–
2008). Further, the cancer rates for Cyprus used in the
comparison with other countries were derived from the
present study, not from CI5. Information regarding
smoking prevalence for the years 1990 and 2000 was ex-
tracted from a published article by Ng et. al. [25]. These
years were chosen due to the lag period between tobacco
exposure and cancer onset. Although a large number of
cancers are related to tobacco and smoking, our study is
limited to three main tobacco-related cancers: head/neck
and oral, lung, and urinary/bladder cancers.
Statistical analysis
The cancer patient population was divided into two
groups, tobacco-related cancers and all other cancers.
Tobacco-related cancers included: lung, urinary bladder,
oral, pharyngeal, head and neck, and laryngeal cancers.
Univariate analysis comparing tobacco-related cancers
and all other cancers were conducted with regards to
age at diagnosis, age groups (0–25, 26–50, 51–75, 76+),
sex, smoking status, disease stage, and rural/urban sta-
tus, with a p-value of 0.05 considered significant. For all
tobacco-related cancers and for some sub-groups, such
as lung; head, neck, and oral; and urinary and bladder
cancer categories, we calculated world age-standardized
incidence rates for the whole period of 1998 – 2008
using the WHO 2000–2025 Standard for each sub-
district [26]. “World age-standardized rates” are rates
that were adjusted using the world population as the ref-
erence population. In addition, world age-standardized
incidence rates were calculated for each gender and
compared by rural and urban case location. The age
standardized rates for selected cancers were visualized
by sub-district, to show geographic variation in cancer
types. All statistical analyses were conducted using SAS
9.4 (Cary, NC) and maps were created using ESRI’s
ArcMap 10.2 (Redlands, CA).
Results
There were 22,415 patients in the CyCR during 1998–
2008. Of these, 3,635 patients were diagnosed with
tobacco-related cancers and 18,780 with other cancers
(Table 1). We included cancers of lung, urinary bladder,
oral pharyngeal, head and neck, and laryngeal cancers in
the tobacco-related cancers group. Patients diagnosed
with tobacco-related cancers were older than their non-
tobacco related counterparts (mean age 67.2 ± 12.4 vs.
62.4 ± 17.1, p < 0.0001). The majority of patients in the
tobacco-related (63.4 %) and all other cancers (55.2 %)
were in the 51–75 age group. Male gender was associ-
ated with the presence of tobacco-related cancers (OR
Fig. 1 Proportion of smokers in the general population by urban and rural areas of sub-districts
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4.82, 95 % CI: 4.43-5.26). Among those with tobacco-
related cancers, 80.1 % were male compared to 45.4 %
males among those with other cancers. A higher propor-
tion of patients who were ever smokers (current or
former smokers) were found among patients with
tobacco-related cancers (47.3 %) compared to patients
with other cancers (19.8 %), p-value < 0.0001 (Table 1).
Although the proportion of ever smokers was higher
among males compared to females in both urban and
rural districts in the general population (Fig. 1), the as-
sociation was stronger in rural areas compared to
urban (OR 13.4, 95 % CI: 8.44-21.28 vs. OR 9.4, 95 %
CI: 6.83-12.23) (data not shown).
In addition, stage of diagnosis varied by cancer diagno-
sis group (p-value <0.0001). Among patients with
tobacco-related cancers, the majority (44.8 %) were diag-
nosed at local stage, followed by 18.4 % at distant stage.
Among patients with other cancers, 40.4 % were diag-
nosed at local stage and 23.8 % at regional stage.
Tobacco-related cancers were further classified into
lung, head and neck/oral, and urinary bladder cancers.
Head and neck/oral cancers included lip, tongue, mouth,
salivary glands, tonsil, other oropharynx, nasopharynx,
hypopharynx, pharynx unspecified, nose/sinuses, and
larynx.
There were significant geographic variations among
these cancer types by sub-district (Table 2 and Fig. 2).
For example, the age adjusted rate (AAR) for tobacco-
related cancers was the highest for sub-district 41 in
Larnaka (AAR 41.9, 95 % CI: 35.7-48.1), sub-district 60
in Pafos (AAR 40.3, 95 % CI: 35.2-45.3), and sub-district
50 in Lemesos (AAR 36.3, 95 % CI: 33.8-38.7). The age-
adjusted tobacco-related cancer incidence rate was the
lowest for sub-district 42 in Larnaka (AAR 20.7, 95 %
CI: 13.3-28.0) and sub-district 53 in Lemesos (AAR 24.6,
95 % CI: 19.3-29.9). Furthermore, the age adjusted inci-
dence rate of lung cancer was the highest in sub-district
41 in Larnaka (AAR 23.8, 95 % CI: 19.2-28.5). Also, the
rates of both head and neck/oral and lung cancer were
the highest in Pafos: AAR 12.1 (95 % CI: 1.5-22.7) in
sub-district 62 and AAR 13.5 (95 % CI: 10.5-16.4) in
sub-district 60, respectively.
The age-adjusted incidence rates for all tobacco-
related cancers were higher in males than in females, in-
dependent of urban/rural living status. For lung and
urinary/bladder cancers rates were higher in urban com-
pared to rural areas, while head and neck/oral cancers
were lower in urban compared to rural areas (Table 3,
Fig. 2). The largest difference between urban and rural
areas were found in females with lung cancer (RR 1.4)
and males with urinary/bladder cancer (RR 1.4). The
overall tobacco-related cancer rate was the highest
among males in the urban districts (AAR 60.8, 95 % CI:
58.2-63.5). Males from the urban areas had the highest
lung cancer (AAR 30.9, 95 % CI: 29.0-32.8) and urinary/
bladder cancer age-adjusted incidence rates (AAR 21.6,
95 % CI: 20.0-23.2) (Table 3).
Tables 4 and 5 examine the differences in daily smok-
ing prevalence for a number of European countries, and
compare them to the prevalence of lung and bladder
cancers. Among males 65–69 years old (Table 4), only
Latvia had a higher smoking prevalence than Cyprus in
1990; in 2000, Denmark, Estonia, Lithuania, and Latvia
had higher proportions of daily smokers than Cyprus.
However, with regard to cancer, all countries except for
Sweden exhibited a higher lung cancer rate than Cyprus.
For bladder cancer, seven countries exhibited higher
rates than Cyprus, despite having similar or lower smok-
ing prevalence. Table 5 examines the smoking and can-
cer rates among 65–69 year-old females. There were 12
countries that had a higher smoking prevalence than
Cyprus in 1990 and/or 2000; these countries also had
higher lung and/or bladder cancer rates.
Similar patterns in smoking prevalence and cancer rates
were found for the same countries among 60–64 year-old
adults. Latvia was the only country that exhibited a higher
Table 1 Comparison of characteristics between participants
diagnosed with tobacco-related cancer compared to all other
cancers
Characteristics Other cancers Tobacco-related Cancers1 p-value
N = 18,780 % N = 3,635 %
Age at Diagnosis
Mean Age (StD) 62.4 (17.1) 67.2 (12.4) <0.0001




Male 8526 45.4 2910 80.1 <0.0001
Female 10254 54.6 725 19.9
Smoking Status
Ever smoker 3719 19.8 1721 47.3 <0.0001
Never smoker 5428 28.9 471 13.0
Unknown 9633 51.3 1443 39.7
Stage
Local 7584 40.4 1630 44.8 <0.0001
Regional 4472 23.8 596 16.4
Distant 3219 17.1 669 18.4
Unstaged 3505 18.7 740 20.4
Location
Urban 13015 69.3 2476 68.1 0.1563
Rural 5765 30.7 1159 31.9
Notes:
1Tobacco-related cancers include: lung, urinary bladder, oral, pharyngeal, head
and neck, and laryngeal cancers
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proportion of male daily smokers than Cyprus (for the
year 2000), however every country except for Sweden ex-
hibited higher rates of lung cancer. Additionally, six
countries exhibited higher rates of bladder cancer than
Cyprus despite lower proportions of daily smokers
(data not shown).
Discussion
This study revealed the following interesting observations.
First, tobacco-related malignancies were more common
among older males and ever smokers compared to non-
tobacco-related malignancies. Second, there were distinct
variations in AARs of tobacco-related malignancies for the
sub-districts of Cyprus. Third, we found that age-adjusted
incidence rates were also at least three times as high for
males compared to incidence rates among females for all
tobacco-related cancers (lung, head/neck/oral, and urinary
bladder). Furthermore, among tobacco-related cancers,
lung cancer had the highest overall AAR while head and
neck/oral cancer had the lowest overall AAR. Lastly,
tobacco-related cancer rates for Cyprus in this study were
lower than the rates of the same cancers reported from
other countries.
The large proportion of tobacco-related cancers in
males compared to females observed in this study is sup-
ported by the higher number of Cypriot men who re-
ported smoking than women in the 2003 and 2008 health
surveys [17]. A previous meta-analysis of 254 studies also
found that among various cancer sites, male smokers had
higher relative risks for developing respiratory cancers
than females [27]. Additionally, a larger proportion of
tobacco-related cancers were in patients between the ages
of 51 and 75 compared to non-tobacco related cancers.
This could be due to the long lag period needed for the
development of tobacco-related malignancies following to-
bacco exposure [23, 28, 29].
The highest AARs of all tobacco-related cancers were
found in sub-district 41 of Larnaka, followed by sub-
districts 60 of Pafos and 50 of Lemesos. However, Larnaka
and Lemesos were also home to the lowest AARs of all
tobacco-related cancers (in sub-districts 42 and 53, re-
spectively). The intra- and inter-district variations are
Table 2 Age-adjusted rates (per 100,000 persons) of tobacco-related cancers by Sub-District
District Sub-
District
All Tobacco-related Cancers Lung Head and Neck/Orala Urinary/Bladder
AAR 95 % CI AAR 95 % CI AAR 95 % CI AAR 95 % CI
Lefkosia 10 34.5 32.4-36.6 18.9 17.4-20.5 4.3 3.6-5.1 11.2 10-12.4
11 28.9 22.1-35.7 17.5 12.2-22.8 3.3 1.0-5.5 8.1 4.6-11.7
12 25.5 20.9-30.2 13.2 9.9-16.6 6.2 3.8-8.6 6.1 3.8-8.4
13 31.2 24.3-38.1 17.2 12.2-22.2 4.6 1.8-7.5 9.4 5.5-13.2
14 28.4 21.3-35.5 14.1 9.3-18.8 7.4 3.0-11.8 6.9 3.6-10.2
Total 33.1 31.3-34.8 18.4 17.1-19.7 4.5 3.9-5.2 10.1 9.2-11.1
Ammochostos 31 32.2 27.3-37.2 16.3 12.8-19.9 7.2 4.8-9.6 8.7 6.1-11.2
Larnaka 40 30.0 26.7-33.3 15.0 12.6-17.3 4.9 3.5-6.2 10.1 8.2-12.1
41 41.9 35.7-48.1 23.8 19.2-28.5 6.4 3.9-8.8 11.7 8.4-14.9
42 20.7 13.3-28.0 9.7 4.6-14.8 RSb RSb 8.1 3.5-12.7
43 31.6 21.5-41.6 21.9 13.2-30.7 RSb RSb 7.1 2.9-11.3
Total 32.3 29.7-35.0 17.3 15.3-19.2 4.9 3.8-6.0 10.2 8.7-11.6
Lemesos 50 36.3 33.8-38.7 17.8 16.1-19.5 5.5 4.5-6.5 13.0 11.5-14.5
51 28.6 22.1-35.1 14.8 10.2-19.5 3.7 1.3-6.0 10.1 6.3-14.0
52 32.6 25.6-39.7 13.7 9.2-18.2 8.3 4.7-12.0 10.6 6.7-14.5
53 24.6 19.3-29.9 9.0 5.8-12.1 6.8 3.8-9.9 8.8 5.8-11.8
Total 35.0 32.9-37.1 17.2 15.7-18.6 5.7 4.8-6.5 12.1 10.9-13.3
Pafos 60 40.3 35.2-45.3 19.3 15.8-22.8 7.5 5.3-9.7 13.5 10.5-16.4
61 33.8 26.4-41.2 17.7 12.4-23.1 6.7 3.3-10.1 9.3 5.4-13.2
62 30.6 18.1-43.0 8.0 2.5-13.5 12.1 1.5-22.7 10.5 4.0-17.0
63 35.3 26.2-44.5 17.9 11.4-24.4 RSb RSb 13.1 7.9-18.4
Total 36.7 33.2-40.3 18.3 15.8-20.8 6.7 5.1-8.3 11.7 9.7-13.6
aIncludes: Lip, tongue, mouth, salivary glands, tonsil, other oropharynx, nasopharynx, hypopharynx, pharynx unspecified, nose/sinuses, larynx
bRates were suppressed (RS) if less than 5 cases were reported in a sub-district
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Fig. 2 Age-adjusted cancer incidence rates (per 100,000 persons) by Sub-District for all tobacco-related cancers combined, lung cancer, head/neck/oral
cancer, and urinary/bladder cancer
Table 3 Age-adjusted rates (per 100,000 persons) for urban and rural residence for tobacco-related cancers
Cancer location Overall AAR Urban AAR Rural AAR Rate Ratio Urban:Rural
AAR 95 % CI AAR 95 % CI AAR 95 % CI RR 95 % CI
Tobacco-related: All 33.9 32.8-35.0 35.4 34.0-36.8 31.4 29.6-33.2 1.1a 1.1-1.2
Males 57.9 55.8-60.0 60.8 58.2-63.5 53.2 49.7-56.6 1.1a 1.1-1.2
Females 13.0 12.0-13.9 13.6 12.4-14.8 11.9 10.3-13.4 1.1 1.0-1.9
Lung 17.8 17.0-18.6 18.6 17.6-19.6 16.5 15.2-17.8 1.1 1.0-1.2
Males 29.9 28.4-31.5 30.9 29.0-32.8 28.6 26.1-31.1 1.1 1.0-1.2
Females 7.3 6.5-8.0 8.0 7.1-9.0 5.8 4.7-6.8 1.4a 1.1-1.7
Head and Neck/Oralb 5.3 4.8-5.7 5.1 4.5-5.6 5.8 5.0-6.6 0.9 0.7-1.1
Males 8.5 7.7-7.7 8.3 7.3-9.3 8.8 7.4-10.3 0.9 0.8-1.2
Females 2.4 2.0-2.8 2.2 1.7-2.7 2.9 2.1-3.8 0.7 0.5-1.1
Urinary/Bladder 10.8 10.2-10.2 11.8 11.0-12.6 9.1 8.1-10.0 1.3a 1.1-1.5
Males 19.5 18.2-18.2 21.6 20.0-23.2 15.8 13.9-17.6 1.4a 1.2-1.6
Females 3.3 2.9-2.9 3.4 2.8-4.0 3.2 2.4-3.9 1.1 0.8-1.5
aRate Ratio is statistically significant (p < .05)
bIncludes: Lip, tongue, mouth, salivary glands, tonsil, other oropharynx, nasopharynx, hypopharynx, pharynx unspecified, nose/sinuses, larynx
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likely to be influenced by the proportion of rural and
urban Cypriot smokers. As of 2008, nearly one-third of
the Cyprus urban population reported smoking, as shown
in Fig. 1, while rural areas reported smaller percentages
[18]. The observed high number of urban smokers coin-
cides with the finding from our study that the highest
rates of cancer were in sub-districts 60 and 50, both of
which are urban. It is possible that although sub-district
41 is rural, residents are more exposed to environmental
risks than neighboring sub-districts, thereby leading to in-
creased cancer rates within the sub-district. Such environ-
mental risks include chemical exposures from farming
and the proximity to an oil refinery that was active up to a
few years ago. It is also possible that residents from sub-
district 41 smoke more frequently than others from neigh-
boring sub-districts; however, data on smoking prevalence
in each sub-district is not available. Further studying is
needed to identify what gives rise to the high rate of can-
cer in a rural sub-district.
The observations regarding sub-districts 60 and 50
were further supported when the data was stratified by
urban versus rural populations of Cyprus. The AAR for
all tobacco-related cancers combined was higher in
urban compared to rural populations. While multiple
factors, such as the environment or occupational expo-
sures, are related to the urban and rural differences in
cancer rates, the clearly higher prevalence of smoking in
urban areas is likely an important factor [30, 31]. A
smoking pattern similar to what is shown in Fig. 1 was
found in Greece, where marked differences in smoking
between rural and urban residents of similar age ranges
and educational status were observed [32]. Other European
countries, such as Poland, also reported higher proportions
of smokers in urban (nearly one-third) compared to rural
areas (about one-fourth) [31].
It should be noted that the AAR for head and neck
cancer found in our study was higher for rural than
urban populations. This could be due to a number of
factors, such as differences in alcohol consumption, in-
fections, or nutritional deficiencies. Although interesting,
the exact cause of this observation is unknown and
should be further examined.
Table 4 Smoking prevalence among males ages 65–69 years in
1990 and 2000 compared to cancer rates for adults ages 15+
(1998–2007)




Cyprus 32 % (17-41 %) 32 % (20-47 %) 29.9 19.5
Sweden 22 % (18-27 %) 17 % (14-21 %) 20.8 17.4
Sloveniab 19 % (9-32 %) 16 % (9-26 %) 57.7 16.7
Finlandb 15 % (11-20 %) 13 % (11-16 %) 35.8 13.9
Maltab 27 % (14-44 %) 24 % (15-34 %) 36.8 25.5
Slovakia b 11 % (5-20 %) 6 % (3-10 %) 58.7 15.4
Denmarkc b 29 % (25-34 %) 34 % (30-39 %) 45.6 26.4
Netherlandsb 27 % (24-31 %) 17 % (14-21 %) 52.0 14.2
United Kingdomb 25 % (22-29 %) 20 % (18-22 %) 42.9 21.1
Germanyb 28 % (23-34 %) 18 % (15-22 %) 58.9d 19.0d
Italyb 29 % (25-34 %) 21 % (18-24 %) 53.2 33.9
Austriab 24 % (17-31 %) 22 % (16-28 %) 44.2 22.5
Franceb 26 % (22-31 %) 17 % (13-21 %) 52.5 19.3
Czech Republicb 20 % (10-32 %) 22 % (16-28 %) 61.5 20.0
Estoniacb 32 % (18-49 %) 36 % (23-50 %) 60.8 16.0
Spainb 28 % (24-34 %) 24 % (20-28 %) 49.2 34.8
Lithuaniacb 26 % (14-43 %) 36 % (20-52 %) 61.3 16.4
Latviacb 37 % (22-56 %) 44 % (29-58 %) 62.0 15.4
UI Uncertainty intervals
aPer 100,000. Cancer rates for Cyprus are derived from the present study.
Cancer rates from all other countries are from CI5 (1998–2007)
bThese countries had higher lung and/or bladder cancer rates than Cyprus
cThese countries had a higher smoking prevalence than Cyprus for 1990
and/or 2000
dOnly includes the German state of Saarland
Table 5 Smoking prevalence among females ages 65–69 years
in 1990 and 2000 compared to cancer rates for adults ages 15+
(1998–2007)




Cyprus 6 % (2-14 %) 7 % (3-14 %) 7.3 3.3
Swedenbc 18 % (12-23 %) 15 % (12-19 %) 15.9 5.0
Sloveniabc 8 % (3-17 %) 7 % (3-13 %) 14.2 3.8
Finlandbc 6 % (4-9 %) 8 % (6-10 %) 10.2 2.9
Maltabc 8 % (3-17 %) 6 % (3-11 %) 6.4 5.3
Slovakiac 5 % (2-11 %) 5 % (2-9 %) 9.4 3.5
Denmarkbc 33 % (28-39 %) 30 % (25-34 %) 33.4 7.7
Netherlandsbc 14 % (11-17 %) 14 % (11-18 %) 22.6 3.4
United Kingdombc 24 % (20-29 %) 19 % (17-22 %) 24.6 6.1
Germanybc 10 % (7-14 %) 10 % (7-12 %) 19.2d 5.1d
Italybc 12 % (9-15 %) 10 % (8-11 %) 12.7 6.2
Austriabc 9 % (6-14 %) 12 % (8-17 %) 15.4 5.7
Francebc 10 % (8-13 %) 9 % (6-12 %) 11.1 2.9
Czech Republicbc 14 % (6-26 %) 12 % (8-18 %) 14.9 5.3
Estoniac 4 % (2-10 %) 5 % (2-11 %) 8.8 2.9
Spainc 6 % (4-8 %) 4 % (3-5 %) 6.0 4.5
Lithuania 2 % (1-5 %) 2 % (1-5 %) 6.6 3.0
Latviac 5 % (2-11 %) 6 % (3-12 %) 7.7 2.7
UI Uncertainty intervals
aPer 100,000. Cancer rates for Cyprus are derived from the present study.
Cancer rates from all other countries are from CI5 (1998–2007)
bThese countries had a higher smoking prevalence than Cyprus for 1990
and/or 2000
cThese countries had higher lung and/or bladder cancer rates than Cyprus
dOnly includes the German state of Saarland
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In our study, cancer rates were higher in males than
females in the lung, head and neck, and urinary/bladder
in both rural and urban settings. Again, a main factor
contributing to this gender difference in cancer rates
could be the greater number of men who smoke com-
pared to women [17, 33]. The 2008 European Health
Survey found that, on average, men smoked 24 cigarettes
per day whereas women smoked an average of 15 ciga-
rettes per day [18]. There may also be gender differences
in the additional risk factors previously mentioned that
contribute to the development of cancer. These should
be taken into consideration in future studies.
Among the different cancer sites, the highest overall
AAR was found for lung cancer whereas the lowest was
for head and neck. Although a causal relationship exists
between smoking and both cancer sites, it is interesting
that one anatomic site showed higher rates of cancer
than the other, despite both being exposed to tobacco
during smoking or other methods of tobacco inhalation.
A possible reason for this rate difference is the high rate
of cell-turnover of epithelial cells in the oral cavity and
esophagus, and the higher susceptibility to damage of al-
veolar cells in the lungs [34, 35]. For other tobacco-
related cancer sites exposure to the effect of smoking is
secondary. For example, bladder cells are exposed to car-
cinogens that accumulate in the urine after they have
been carried through the bloodstream, whereas cells of
the lungs are directly exposed to tobacco smoke [36, 37].
Another factor that could give rise to the different
incidence rates of cancer in various sites is the type of
tobacco product and inhalation pattern. The smoke pro-
duced from pipes and cigars irritate and damage the
pharynx, as opposed to damaging the alveoli of the lungs
[29]. Conversely, smokers inhale more deeply when
using cigarettes, thereby increasing the concentration of
smoke and carcinogens within their lungs [29]. Accord-
ing to the 2008 Health Survey, the prevalence of
cigarette smoking among male smokers was 38.9 %,
while the prevalence of cigar and pipe smoking was only
1.4 %. For females, the prevalence of cigarette smoking
was 14.4 % and there was no reported cigar or pipe
smoking [18].
Although there is a strong causal relationship between
smoking and the various cancer sites studied, there are
also other risk factors associated with the development
of disease, which may be less prevalent in Cyprus com-
pared to other countries. These include genetic polymor-
phisms, infections (e.g. human papillomavirus), ionizing
radiation, organic chemicals, air pollution and occupa-
tional exposures [23, 29, 38–40]. For example, in
Romania, which has much higher lung cancer rates than
Cyprus, the population is exposed to radon gas in dwell-
ings. A study estimated that in two different counties in
Romania (Cluj and Bistrita), 9.09 % and 5.66 % of lung
cancers in non-smokers were attributed to radon, respect-
ively [41]. Thus, information regarding different exposures
in cancer patients is imperative to understanding the eti-
ology of their disease. In addition, future investigations
should explore the histological subtypes of lung cancer in
these populations with different lung cancer incidence.
Another interesting potential difference that is worth in-
vestigating in the future relates to the types of tobacco
smoked in these different countries. Finally, there is a pos-
sibility that differential screening and detection among
these countries may affect the reported incidence of these
cancers, even though Cyprus along with these other coun-
tries follow the European guidelines, which recommend
against lung cancer screening [42, 43].
Despite the high prevalence of smoking within Cyprus,
the observed cancer rates for the country are lower than
the rates in other European countries, especially for
males. It is possible that wind on the island could help
move smoke in the atmosphere, which could contribute
to lower cancer rates. This pattern of high smoking rates
paired with low tobacco-related cancer rates has also
been observed in Japan and aptly called the “Japanese
smoking paradox” [44]. The factors (genetic and/or en-
vironmental) that contribute to this observation are
unknown and should be further studied.
Strengths of this study include the large dataset used
from the Cyprus Cancer Registry, the dataset’s previous
utilization in research and comparisons with other coun-
tries [20, 26], and the use of maps depicting all geographic
regions of Cyprus. However, the ecologic nature of the
study and lack of information regarding measurements of
individual exposures to tobacco limited our ability to draw
conclusions after hypothesis generation. Therefore, future
studies should focus on measuring individual exposures to
tobacco smoke and understanding smoking behaviors in
addition to other possible etiologic factors in the develop-
ment of tobacco-related malignancies.
Conclusions
In conclusion, this study illustrates higher rates of
tobacco-related cancers in males than females in Cyprus.
The study also reveals geographic differences between
districts and sub-districts and differences in incidence
between individual types of tobacco-related cancers. The
study illustrates lower incidence tobacco-related cancers
in Cyprus compared to other countries with similar
smoking rates. Future studies should be in-depth with
individual measurements of different types of smoking
and account for other risk factors of tobacco-related ma-
lignancies. Since tobacco-related cancer rates in Cyprus
are low despite high smoking prevalence, understanding
the factors that contribute to the lower cancer incidence
will have important implications for cancer prevention.
These factors could be genetic and/or environmental
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and their identification is essential in order to reduce
tobacco-related cancer incidence in other populations.
Furthermore, although tobacco-related cancer rates are
low within Cyprus, smoking cessation should still be em-
phasized to further reduce the burden of cancer and
other side effects related to smoking.
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